Cargando…

Population Pharmacokinetics of Palbociclib in a Real-World Situation

Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Its metabolism profile is associated with an important interpatient variability. We performed a population pharmacoki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Royer, Bernard, Kaderbhaï, Courèche, Fumet, Jean-David, Hennequin, Audrey, Desmoulins, Isabelle, Ladoire, Sylvain, Ayati, Siavoshe, Mayeur, Didier, Ilie, Sivia, Schmitt, Antonin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996283/ https://www.ncbi.nlm.nih.gov/pubmed/33668400 http://dx.doi.org/10.3390/ph14030181

Ejemplares similares

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
por: Marouille, Alexandre Le, et al.
Publicado: (2021)

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results
por: Réda, Manon, et al.
Publicado: (2023)

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
por: Galland, Loïck, et al.
Publicado: (2023)

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022)

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
por: Galland, Loïck, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study
por: Ladoire, Sylvain, et al.
Publicado: (2021)

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study
por: Ladoire, Sylvain, et al.
Publicado: (2022)

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
por: Ilie, Silvia Mihaela, et al.
Publicado: (2023)

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
por: Kaderbhaï, Courèche, et al.
Publicado: (2019)

Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life
por: Dalens, Lorraine, et al.
Publicado: (2022)

Implementation and use of whole exome sequencing for metastatic solid cancer
por: Réda, Manon, et al.
Publicado: (2020)

Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers
por: Bergeron, Anthony, et al.
Publicado: (2023)

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020)

Cross-sectional nationwide mixed-methods population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: the Candy study protocol
por: Assogba, Emerline L F, et al.
Publicado: (2022)

Small Cell Neuroendocrine Carcinoma of the Paranasal Sinuses with Unexpected Location and Clinical Presentation and Occupational Exposure: A Case Report
por: Tankere, Pierre, et al.
Publicado: (2022)

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer
por: Courlet, Perrine, et al.
Publicado: (2022)

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
por: Galland, Loïck, et al.
Publicado: (2021)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study
por: Mamguem Kamga, Ariane, et al.
Publicado: (2021)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Cutaneous manifestations in patients with coronavirus disease 2019: clinical and histological findings()()
por: Fattori, Antonin, et al.
Publicado: (2021)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

High-pressure intrapleural chemotherapy: feasibility in the pig model
por: Facy, Olivier, et al.
Publicado: (2012)

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
por: Kaderbhai, Coureche Guillaume, et al.
Publicado: (2016)

Palbociclib in the treatment of recurrent ovarian cancer
por: Lee, Dai Wee, et al.
Publicado: (2020)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
por: Leenhardt, Fanny, et al.
Publicado: (2022)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Neutropenia due to palbociclib: A word of caution?
por: Pramanik, Raja, et al.
Publicado: (2016)

Palbociclib: COVID-19 infection: case report
Publicado: (2020)

Lysosomal trapping of palbociclib and its functional implications
por: Llanos, Susana, et al.
Publicado: (2019)

Palbociclib: Myelosuppression and gastrointestinal reactions: case report
Publicado: (2022)

Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry
por: Kada Mohammed, Samia, et al.
Publicado: (2022)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0qu3rr8sb200reccnb2b0cbebq